Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

Mary O’Brien, Luis Paz‐Ares, Sandrine Marréaud, Urania Dafni, Kersti Oselin, Libor Havel, Emilio Esteban, Dolores Isla, Alex Martínez‐Martí, Martin Faehling, Masahiro Tsuboi, Jong Seok Lee, Kazuhiko Nakagawa, Jing Yang, Ayman Samkari, Steven M. Keller, Murielle Mauer, Nitish Jha, Rolf A. Stahel, Benjamin Besse, Solange Peters